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Abstract: 
We sought to assess the performance of existing bleeding risk scores, such as HAS-BLED or OBRI, 
in patients with heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (SR) treated 
with warfarin or aspirin. We calculated HAS-BLED and OBRI risk scores for 2,305 patients with 
HFrEF in SR enrolled in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction 
(WARCEF) trial. Proportional hazards models were used to test whether each score predicted 
major bleeding, and comparison of different risk scores was performed using Harell’s c-statistic 
and net-reclassification improvement (NRI) index. For the warfarin arm, both scores predicted 
bleeding risk, with OBRI having significantly higher c-statistic (0.72 vs 0.61; p=0.03) compared to 
HAS-BLED, though the NRI for comparing OBRI to HAS-BLED was not significant (0.32, 95% CI -
0.18-0.37). Performance of the OBRI and HAS-BLED risk scores were similar for the aspirin arm. 
For participants with OBRI score of 0 to 1, warfarin compared with aspirin reduced ischemic 
stroke (HR 0.51, 95% CI 0.26-0.98, p=0.042) without significantly increasing major bleeding (HR 
1.24, 95% CI 0.66-2.30, p=0.51).  For those with OBRI score of ≥2, there was a trend for reduced 
ischemic stroke with warfarin compared to aspirin (HR 0.56, 95% CI 0.27-1.15, p=0.12), but 
major bleeding was increased (HR 4.04, 95% CI 1.99-8.22, p<0.001). In conclusion, existing 
bleeding risk scores can identify bleeding risk in HFrEF patients in SR, and could be tested for 
potentially identifying patients with a favorable risk / benefit profile for antithrombotic therapy 
with warfarin. 
 
Keywords: Heart failure, sinus rhythm, warfarin, aspirin, bleeding 
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Introduction 
Patients with heart failure with reduced ejection fraction (HFrEF) may be at increased 
risk for ischemic strokes due to left ventricular thrombus formation and subsequent 
embolism.
1,2
 Randomized clinical trials, such as the Warfarin and Antiplatelet Therapy in Chronic 
Heart Failure (WATCH) trial
3
 and the Warfarin versus Aspirin in Reduced Cardiac Ejection 
Fraction (WARCEF) trial,
4
 assessed whether warfarin therapy may benefit HFrEF patients who 
are in sinus rhythm (SR) and have no other indications for anticoagulation. Although warfarin 
therapy was found to reduce the risk of ischemic stroke in these trials, it also led to increased 
rates of major bleeding.
3,4
 A better characterization of bleeding risk in HFrEF patients who are in 
SR may therefore identify a subgroup of these patients who could benefit from anticoagulation. 
One potential approach is to consider existing bleeding risk scores, such as the HAS-BLED score 
and the Outpatient Bleeding Risk Index (OBRI), which has been used to predict risk of bleeding in 
patients receiving anticoagulation.
5-9
 The HAS-BLED score, in particular, has demonstrated 
superior performance compared to other bleeding risk scores in patients with atrial 
fibrillation,
6,10
 while the OBRI has been noted to be simple to calculate and has been validated in 
outpatients receiving warfarin therapy for any indication.
7,11
 However, it is unknown whether 
these risk scores can also apply to HFrEF patients who are in SR treated with warfarin or aspirin. 
We therefore undertook the present analysis of the patients enrolled in the WARCEF trial, to 
determine whether HAS-BLED and OBRI scores predicted bleeding risk in patients with HFrEF 
who are in SR, and to assess whether the effects of warfarin compared with aspirin varied 
depending on baseline risk of bleeding in this patient population. 
Methods 
The protocol for the randomized, double blinded WARCEF trial 
(http://www.ClinicalTrials.gov No. NCT00041938) has been described previously.4,12 Briefly, 
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patients with left ventricular ejection fraction (LVEF) ≤35% and who were in SR were 
randomized to receive warfarin (target INR 2.75, with acceptable target range of 2.0 to 3.5) or 
aspirin (325mg daily). Additional eligibility criteria included being 18 years or older, having no 
contraindications to warfarin therapy, having a modified Rankin score of 4 or less (on a scale of 0 
to 6, with higher scores indicating more severe disability), and treatment with a beta-blocker, an 
angiotensin-converting-enzyme (ACE) inhibitor or angiotensin-receptor blocker (ARB), or 
hydralazine and nitrates. Patients were excluded if they had a clear indication for warfarin or 
aspirin, or if they had a condition that conferred a high risk of cardiac embolism, such as atrial 
fibrillation, a mechanical cardiac valve, endocarditis, or an intracardiac mobile or pedunculated 
thrombus. Patients were also excluded if they were unable to follow an outpatient study 
protocol, or if they were unable to provide informed consent. Patients in any NYHA functional 
class were eligible, although patients in NYHA class I could account for no more than 20% of the 
total sample. A total of 2,305 participants were recruited from 168 centers in 11 countries from 
October 2002 to January 2010. The investigation conforms with the principles outlined in the 
Declaration of Helsinki, and the Institutional Review Boards at the coordinating centers for all 
sites approved the study. All subjects provided informed consent. The maximum follow-up time 
was 6 years, and the minimum was 1 year.  
Major bleeding was defined as intracerebral, epidural, subdural, subarachnoid, spinal 
intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin 
level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more 
units of whole blood, hospitalization, or surgical intervention. This definition corresponds closely 
to the definition for major bleeding recommended by the Internal Society on Thrombosis and 
Haemostasis.13 Ischemic stroke was defined as a clinically relevant new lesion detected on 
computed tomography or magnetic resonance imaging (MRI) or, in the absence of a new lesion, 
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clinical findings that were consistent with the occurrence of clinical stroke and that lasted for 
longer than 24 hours. An independent end-point adjudication committee, whose members were 
unaware of the treatment assignments, adjudicated all bleeding and stroke events. 
Demographic characteristics including age, sex, race/ethnicity, and body mass index 
(BMI) were determined at the initial study visit. Health behaviors were assessed by self-report at 
time of enrollment, including smoking status and alcohol consumption. Clinical characteristics 
that were collected include medical comorbidities (atrial fibrillation, hypertension, diabetes 
mellitus, history of myocardial infarction, and history of ischemic heart disease), history of 
stroke or transient ischemic attacks (TIAs), presence of liver impairment (defined as having an 
aspartate aminotransferase [AST] level of 114 IU/L, which represents three times the upper limit 
of normal), renal impairment (defined as having a creatinine clearance level of <30 ml/min, 
estimated through the Cockcroft-Gault equation), anemia (defined as having a hematocrit of 
<30%), left ventricular ejection fraction (measured by quantitative echocardiography or 
radionuclide or contrast ventriculography), New York Heart Association (NYHA) functional class, 
and time-in-therapeutic range (calculated as the percentage of days when the INR is between 
2.0 to 3.5). Additional details for these measures are as described previously.
4
  
 For each patient, the HAS-BLED risk score was calculated based on the approach 
described by Lip and colleagues,
6
 with modifications as described below. Because the HAS-BLED 
risk score was derived in patients on anticoagulation therapy, and because all patients in the 
WARCEF trial received either aspirin or warfarin but not both concurrently, the item for aspirin 
use in the HAS-BLED score was coded as 0 for all patients. Furthermore, for patients assigned to 
aspirin, the item for labile INR in the HAS-BLED score was coded as 0. For liver impairment, 
based on available data in WARCEF, we used a cut-off for AST level of >114 IU/L. The OBRI score 
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was similarly calculated for each patient using the approach described by Beyth and colleagues.
7
 
A brief summary of how HAS-BLED and OBRI risk scores were calculated is provided in Table 1. 
 Because bleeding risk is expected to differ for patients receiving warfarin and aspirin, we 
performed all analyses separately for the warfarin and aspirin arms of the WARCEF trial on an 
intent-to-treat (ITT) basis. For each arm, baseline demographic and clinical characteristics were 
compared between patients who had a major bleeding event during follow-up versus those who 
did not, using chi-squared tests for categorical variables and student’s t-tests for continuous 
variables. We further tabulated the proportion of participants with and without a major 
bleeding event by HAS-BLED and OBRI scores. 
 To assess whether HAS-BLED and OBRI scores were predictive of major bleeding, we 
constructed separate Cox proportional hazards models with the time to first major bleeding as 
the outcome and HAS-BLED or OBRI scores as ordinal predictor variables. We performed 
statistical testing for trend of increased risk of major bleeding associated with increased HAS-
BLED or OBRI scores. We then calculated the c-statistics and the associated 95% confidence 
intervals (CI) for each proportional hazards model using the R software package “survcomp”. We 
also compared ability of HAS-BLED and OBRI scores to classify bleeding risk for each arm by 
calculating the net reclassification improvement (NRI) index and its associated 95% CIs, using the 
R software package “nricens” as per the methods described by Pencina and colleagues.
14
 
Because the NRI is sensitive to the selection of cut-offs for defining risk categories,
15
 we used a 
two-category (i.e., high risk of bleeding versus low risk of bleeding) approach to calculate the 
NRI, based on the empirically observed rates of major bleeding across HAS-BLED and OBRI 
scores in the WARCEF trial. 
 We further constructed Cox proportional hazards models to assess the effect of warfarin 
versus aspirin on clinical outcomes, including death or ischemic stroke, ischemic stroke, and 
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major bleeding, for subgroups of WARCEF participants defined by high versus low bleeding risk 
through HAS-BLED and OBRI scores. We also tested for interactions between treatment groups 
and bleeding risk for the above outcomes. P-values of <0.05 were considered statistically 
significant for all testing. All statistical analyses were conducted using SAS version 9.3 (SAS 
Institute, Cary, NC) or R version 3.0.1 (R Foundation for Statistical Computing, Vienna, Austria, 
2013). 
 
Results 
 The baseline characteristics of WARCEF participants by treatment group and bleeding 
risk are presented in Table 2. Of the 1,142 patients randomized to warfarin therapy, 66 (5.8%) 
experienced at least one major bleeding event. Those who experienced major bleeding were 
more likely to be 65 years or older, to be female, and to have renal impairment. For those 
randomized to aspirin, 31 (2.7%) of 1,163 patients had at least one major bleeding event, with 
those with major bleeding more likely to have lower BMI, to have had a prior stroke or TIA, to 
have renal impairment, and to have a previous history of alcohol use. 
 The distribution of HAS-BLED and OBRI scores for patients with and without major 
bleeding were calculated for each arm of the WARCEF trial (Table 3 and Figure 1). The 
proportion of patients who had any major bleeding on warfarin therapy was 5.3% for those with 
a HAS-BLED score of 0, increasing to 12.0% for those with a HAS-BLED score of 4 or above 
(p=0.015 for trend). For those randomized to aspirin, the proportion of patients who had any 
major bleeding was 2.0% for those with a HAS-BLED score of 0, increasing to 6.3% for those with 
a HAS-BLED score of 4 or above (p=0.04 for trend; Figure 1, top panel). Similarly, the proportion 
of patients who had any major bleeding on warfarin therapy was 4.0% for those with an OBRI 
score of 0, but was over 10% for those with an OBRI score of 2 or 3 (p=0.01 for trend; Figure 1, 
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bottom panel). For patients randomized to aspirin, the proportion of those who had any major 
bleeding ranged from 2.6% for those with an OBRI score of 0 to 6.1% for those with an OBRI 
score of 3, but the increase was not statistically significant (p=0.38 for trend). Based on these 
results, for subsequent analyses, we defined a patient as having high risk of bleeding as having a 
score of 2 or above for OBRI and a score of 3 and above for HAS-BLED. 
A comparison of the performance of HAS-BLED and OBRI scores for predicting time to 
the first major bleeding event is presented in Table 4. For the warfarin arm, the c-statistic for 
the OBRI score was 0.72 (95% CI, 0.62-0.81), which was significantly superior (p=0.003) to the c-
statistic for the HAS-BLED score, although the NRI for comparing the OBRI to HAS-BLED was not 
significant (0.32, 95% CI -0.18-0.37). For patients randomized to aspirin, the c-statistics for HAS-
BLED and OBRI scores were similar, and the NRI for the OBRI score compared to the HAS-BLED 
score was not significant. 
 The treatment effect of warfarin versus aspirin on clinical outcomes and its interaction 
with major bleeding risk (categorized by OBRI and HAS-BLED scores) are presented in Figure 2. 
For the outcome of major bleeding, there was a significant interaction between the effect of 
warfarin versus aspirin and bleeding risk according to the OBRI score (p=0.006). Patients 
classified as high bleeding risk by an OBRI score of ≥2 had increased risk of major bleeding with 
warfarin compared with aspirin (hazard ratio [HR] 4.04, 95% CI 1.99-8.22, p<0.001), while 
bleeding risk was similar for warfarin versus aspirin in those classified as low bleeding risk by an 
OBRI score of 0 to 1 (HR 1.24, 95% CI 0.66-2.30; p=0.51). There was no significant interaction 
between warfarin versus aspirin and bleeding risk by the HAS-BLED score (p=0.89), though 
warfarin compared with aspirin significantly increased major bleeding in the subgroup with low 
bleeding risk identified a HAS-BLED score of 0 to 2 (HR 2.04, 95% CI 1.19-3.48; p=0.009). 
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For the outcome of ischemic stroke, there was no significant interaction between 
warfarin versus aspirin and bleeding risk defined by either bleeding risk scores (p=0.93 for OBRI 
and 0.48 for HAS-BLED). The effect of warfarin versus aspirin was similar across subgroups of 
bleeding risk, with warfarin significantly reducing ischemic strokes in patients classified as low 
bleeding risk by either score (Figure 2). For the composite outcome of death or ischemic stroke, 
the effect of warfarin versus aspirin was similar and non-significant across all bleeding risk 
subgroups, and there was no significant interaction between treatment assignment and 
bleeding risk subgroups identified with either score. 
 
Discussion 
 In this retrospective analysis of patients enrolled in the WARCEF trial, we found that 
predictors of major bleeding differed between patients receiving warfarin and aspirin, 
suggesting that bleeding risk is affected by both anti-thrombotic choice and patient 
characteristics. Importantly, we confirmed that the HAS-BLED and OBRI bleeding risk scores can 
be used to predict major bleeding in HFrEF patients who are in SR. For patients assigned to 
warfarin, the OBRI score demonstrated superior discrimination to HAS-BLED, though the NRI for 
comparing the OBRI score to HAS-BLED was not significant, which may have been due to the 
relatively low number of bleeding events. For patients assigned to aspirin, the HAS-BLED risk 
score, but not OBRI, was predictive of major bleeding. Furthermore, we found that the increase 
in major bleeding for warfarin compared with aspirin varied by subgroups identified by the OBRI 
score, and that for WARCEF participants with an OBRI score of 0 or 1, warfarin reduced the risk 
of ischemic stroke but did not increase the risk of major bleeding. 
 Given the continued interest in identifying subgroups of heart failure patients that may 
benefit from anticoagulation,16 our analysis to assess bleeding risk in HFrEF patients who are in 
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SR is a timely one. Previously published bleeding risk scores, such as the HAS-BLED and OBRI, 
were derived and validated in cohorts of patients with indications for anticoagulation such as 
atrial fibrillation or venous thromboembolism.
6,7
 Although the WARCEF trial excluded such 
patients, the performance of the HAS-BLED and OBRI scores are comparable to these earlier 
reports. For example, in an analysis of the Stroke Prevention Using an ORal Thrombin Inhibitor in 
Atrial Fibrillation (SPORTIF) III and V trials, Lip and colleagues reported that the c-statistics of 
previously reported bleeding risk scores, including the HAS-BLED and OBRI, ranged from 0.49 to 
0.65 in a cohort of patients receiving warfarin or ximelagatran.
6
 Similarly, in another report by 
Burgess and colleagues, c-statistics for various published bleeding risk scores ranged from 0.61-
0.74 for a real-world cohort of patients on warfarin therapy for diverse indications.
17
 The c-
statistic of 0.72 for the OBRI risk score for WARCEF participants assigned to warfarin therapy is 
therefore near the upper range of what has been reported previously, and suggests that the 
OBRI score may be a useful prediction tool to characterize risk of major bleeding for this patient 
population. 
We also assessed the effect of warfarin versus aspirin on clinical outcomes for 
subgroups of WARCEF patients stratified by predicted bleeding risk. We demonstrated that 
among patients having an OBRI risk score of 0 or 1, who accounted for more than half of all 
ischemic strokes observed during the WARCEF follow-up period, warfarin therapy reduced the 
risk of ischemic stroke compared with aspirin but did not significantly increase the risk of major 
bleeding. These results are broadly consistent with our previous subgroup analysis showing that 
younger patients (age <60 years) enrolled in the WARCEF trial had reduced risk of death, 
ischemic stroke, or intracranial hemorrhage with warfarin therapy compared to aspirin.18 In our 
current analysis, WARCEF participants with an OBRI risk score of 0 or 1 included most patients 
younger than 60 years, but also many patients who are older. Taken together, this subgroup 
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consists of nearly two thirds of all patients enrolled in the WARCEF trial and accounts for more 
than half of all ischemic stroke events observed during the follow-up period. The findings from 
the present analysis therefore provide important insights for predicting the potential outcomes 
of antithrombotic therapies for a large number of patients with HFrEF who are in SR.  
Our findings also raise the possibility of using bleeding risk scores to inform patient 
selection for subsequent trials of novel anticoagulants. Previous studies have often described a 
positive correlation between risk of stroke and risk of bleeding in patients who are candidates 
for oral anticoagulation therapy, as many risk factors, such as advanced age and hypertension, 
are shared by both of these adverse outcomes.
19,20
 This overlap is a major challenge for the use 
of bleeding risk scores as a part of a personalized approach for choosing anticoagulation 
strategy, as patients identified as having high risk of stroke also often have high risk of 
bleeding.
21
 Our results address this challenge by showing that predicted bleeding risk could play 
an important role in patient selection for consideration of antithrombotic therapy. Although 
warfarin compared with aspirin reduced ischemic strokes in WARCEF participants with both high 
and low predicted bleeding risk, the significant interaction between treatment assignment and 
OBRI risk categories for the outcome of major bleeding suggests that patients at low predicted 
bleeding risk may avoid increased bleeding with anticoagulation. Given the emergence of new 
non-vitamin K oral anticoagulants that have demonstrated favorable safety and efficacy profiles 
compared to warfarin,
22
 these findings may be useful for the design of future trials investigating 
the role of these agents for ischemic stroke prevention in HFrEF patients in SR. 
There are a number of limitations to our study. Our retrospective analysis of the 
WARCEF trial had only a modest number of stroke and bleeding events, and our findings 
therefore are necessarily hypothesis generating and will require confirmation. Highlighting the 
challenges of applying existing risk scores to new populations and datasets, we made slight 
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modifications to the HAS-BLED score to apply it to the WARCEF population. Our analysis of the 
performance of the HAS-BLED and OBRI bleeding risk scores will thus require further validation 
in independent cohorts of HFrEF patients who are in SR. However, while a new risk score 
derived from WARCEF data may better predict bleeding risk and estimate treatment effect sizes 
for this patient population, it is also likely that a well-performing, previously established risk 
score accepted by clinicians and practice guidelines will have broader impact.
23
 Finally, since the 
WARCEF trial only enrolled patients with HFrEF who are in SR, our findings may not be 
applicable to other subgroups of heart failure patients. 
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Figure Legends 
 
Figure 1. Proportion of patients with major bleedings, by HAS-BLED and OBRI risk 
scores and by treatment arm.  
 
P-values for trend were calculated using Cox proportional hazards models. 
 
Figure 2. The effect of warfarin versus aspirin on clinical outcomes for subgroups of 
WARCEF participants stratified by OBRI and HAS-BLED risk scores. 
 
P-values represent results of tests of interaction between treatment assignment and 
bleeding risk subgroups identified by OBRI and HAS-BLED risk score. 
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Table 1. Calculation of the HAS-BLED and OBRI risk scores. All risk factors are scored as 1 point each unless otherwise noted. Because the HAS-
BLED risk score was derived in patients on anticoagulation therapy, and because no patient in warfarin received both aspirin and warfarin 
concurrently, aspirin use in the HAS-BLED score was coded as 0 in this analysis. Similarly, for patients assigned to aspirin, the item for labile INR 
in the HAS-BLED score was coded as 0 for these patients. For abnormal liver function, based on available data in WARCEF, a cut-off for AST level 
of >114 IU/L was used. 
 
HAS-BLED Risk Score OBRI Risk Score 
Hypertension (SBP >160 mmHg) Age >65 years 
Abnormal renal/ liver function (1 point for each) History of stroke 
Stroke History of GIB 
Bleeding Recent MI, HCT <30%, Cr >1.5 mg/dL, or diabetes mellitus 
Labile INRs (TTR <60%)  
Elderly (age >65 years)  
Drugs (antiplatelet agents / NSAIDs) or excess alcohol (1 
point for each) 
 
Abbreviations: SBP, systolic blood pressure; TTR, time in therapeutic range; NSAID, non-steroidal anti-inflammatory drugs; GIB, gastrointestinal 
tract bleeding; MI, myocardial infarction; HCT, hematocrit; Cr, creatinine. 
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Table 2. Characteristics of WARCEF participants by warfarin versus aspirin and by major bleeding status during follow-up. 
 
 
Variable 
 
Warfarin 
 
 
 
Aspirin 
 
 
 
 
Major 
bleeding 
(n=66) 
No major 
bleeding 
(n=1076) 
p-value Major 
bleeding 
(n=31) 
No major 
bleeding 
(n=1132) 
p-value 
Age >65 yrs old 36 (55%) 358 (33%) < 0.001 13 (42%) 389 (34%) 0.420 
Women 21 (32%) 215 (20%) 0.021 8 (26%) 216 (19%) 0.349 
Non-Hispanic white 
Non-Hispanic black 
Hispanic 
Other 
45 (68%) 
9 (14%) 
9 (14%) 
3 (6%) 
814 (76%) 
157 (15%) 
76 (7%) 
29 (3%) 
0.182 24 (77%) 
5 (16%) 
1 (3%) 
1 (3%) 
855 (76%) 
161 (14%) 
80 (7%) 
36 (3%) 
0.866 
Body mass index (kg/m
2
) 
      < 25 
      25-30 
      > 30 
 
22 (33%) 
26 (39%) 
18 (27%) 
 
279 (26%) 
400 (37%) 
397 (37%) 
0.228  
16 (52%) 
4 (13%) 
11 (35%) 
 
263 (23%) 
452 (40%) 
417 (37%) 
<0.001 
Hypertension  
Diabetes mellitus 
Atrial fibrillation 
Myocardial infarction 
Ischemic heart disease 
37 (59%) 
23 (35%) 
2 (3%) 
33 (50%) 
33 (50%) 
634 (61%) 
348 (32%) 
42 (4%) 
516 (48%) 
455 (42%) 
0.732 
0.673 
0.721 
0.747 
0.219 
18 (62%) 
7 (23%) 
0 (0%) 
12 (39%) 
9 (29%) 
678 (62%) 
344 (30%) 
42 (4%) 
551 (49%) 
494 (44%) 
0.967 
0.350 
0.275 
0.273 
0.105 
Prior stroke or TIA 14 (21%) 141 (13%) 0.062 8 (26%) 131 (12%) 0.016 
Renal impairment 4 (6%) 22 (2%) 0.033 2 (6%) 16 (1%) 0.026 
Liver impairment 2 (3%) 39 (4%) 0.321 2 (6%) 36 (3%) 0.646 
Anemia, defined as hematocrit < 30% 1 (2%) 3 (0.3%) 0.106 0 (0%) 3 (0.3%) 0.777 
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Smoking status 
Current 
Former  
Never 
 
10 (15%) 
38 (58%) 
18 (27%) 
 
203 (19%) 
547 (51%) 
326 (30%) 
0.549  
6 (19%) 
19 (61%) 
6 (19%) 
 
189 (17%) 
585 (52%) 
358 (32%) 
0.347 
Alcohol consumption 
Current, > 2oz/day 
Previous, >2oz/day 
Never 
 
17 (26%) 
9 (14%) 
40 (60%) 
 
262 (24%) 
241 (22%) 
573 (53%) 
0.240  
6 (19%) 
13 (42%) 
12 (39%) 
 
287 (25%) 
243 (21%) 
602 (53%) 
0.025 
NYHA classification 
I 
II 
III 
IV 
 
8 (12%) 
35 (53%) 
22 (33%) 
1 (2%) 
 
146 (14%) 
596 (55%) 
324 (30%) 
10 (1%) 
0.898  
5 (16%) 
18 (58%) 
8 (26%) 
0 (0%) 
 
163 (14%) 
643 (57%) 
311 (27%) 
15 (1%) 
0.916 
LV ejection fraction (%) 25.3±7.3 24.5±7.5 0.426 24.7±6.1 24.8±7.6 0.932 
TTR <60% 33 (52%) 465 (46%) 0.349 NA NA NA 
Renal impairment is defined as creatinine clearance of <30 ml/min; liver impairment is defined as AST level of >114 IU/L, which 
represents three times the upper limit of normal 
Abbreviations: TIA, transient ischemic attack; NYHA, New York Heart Association; TTR, time in therapeutic range. 
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Table 3. WARCEF participants by warfarin versus aspirin and by bleeding risk according to the HAS-BLED and OBRI scores. Numbers 
in parentheses represent column percents. 
 Warfarin Aspirin 
Risk scores All patients 
(n=1142) 
Major bleeding 
(n=66) 
% with major 
bleeding 
All patients 
(n=1163) 
Major bleeding 
(n=31) 
% with major 
bleeding 
HAS-BLED 
0 
1 
2 
3 
4 
5 
Risk category 
0 to 2 
≥3 
 
76 (7%) 
314 (28%) 
390 (34%) 
287 (25%) 
68 (6%) 
  7 (1%) 
 
780 (68%) 
362 (32%) 
 
4 (6%) 
14 (21%) 
19 (29%) 
20 (30%) 
8 (12%) 
1 (2%) 
 
37 (56%) 
29 (44%) 
 
5.3% 
4.5% 
4.9% 
7.0% 
11.8% 
14.3% 
 
4.7% 
8.0% 
 
150 (13%) 
416 (36%) 
427 (37%) 
154 (13%) 
16 (1%) 
0 (0%) 
 
993 (86%) 
170 (14%) 
 
3 (10%) 
8 (26%) 
12 (39%) 
7 (23%) 
1 (3%) 
0 (0%) 
 
23 (74%) 
8 (26%) 
 
2.0% 
1.9% 
2.8% 
4.5% 
6.3% 
NA 
 
2.3% 
4.7% 
 
OBRI 
0 
1 
2 
3 
Risk category 
0 to 1 
≥2 
 
253 (22%) 
479 (42%) 
371 (32%) 
39 (3%) 
 
732 (64%) 
410 (36%) 
 
10 (15%) 
13 (20%) 
39 (59%) 
4 (6%) 
 
23 (35%) 
43 (65%) 
 
4.0% 
2.7% 
10.5% 
10.3% 
 
3.1% 
10.5% 
 
271 (23%) 
491 (42%) 
368 (32%) 
33 (3%) 
 
762 (23%) 
403 (32%) 
 
7 (23%) 
12 (39%) 
10 (32%) 
2 (6%) 
 
19 (61%) 
12 (39%) 
 
2.6% 
2.4% 
2.7% 
6.1% 
 
2.5% 
3.0% 
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Table 4. Comparison of the HAS-BLED and OBRI risk scores for predicting major bleeding in WARCEF participants receiving warfarin 
or aspirin. 
 
 c-statistic 
for HAS-BLED 
c-statistic 
for OBRI 
p-value for  
difference in c-statistics 
NRI 
Warfarin 0.61 (0.51-0.70) 0.72 (0.62-0.81) 0.03 0.32 (-0.18-0.37) 
Aspirin 0.63 (0.50-0.77) 0.58 (0.43-0.71) 0.50 0.13 (-0.19-0.15) 
Abbreviations: NRI, net reclassification index. For NRI, the directions of comparisons are for OBRI versus HAS-BLED.  
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Supplementary webappendix 
 
WARCEF Committees and Investigators 
 
Executive Committee 
 S. Homma, J.L.P Thompson, P. Pullicino, R. Freudenberger, S. Graham, J. Teerlink, S. 
Ammon, D. Mann, J.P. Mohr, R.L. Sacco, B. Massie, S. Anker, A. Labovitz, and C. Moy 
 
National Institute of Neurological Disorders and Stroke 
C. Moy, P. Gilbert, L. Gutmann, and J. Marler; Clinical Coordinating Center: S. Homma,V. Mejia, 
A. Gabriel, S. Borden, E. Peña, C. Harris, R. Khadouri, D. Gohs, M. Brown, G. Berry, D. 
Disantis, M. Scullin, P. Smith, S. Kohsaka, W. Watson, and L. Guillory; Statistical Coordinating 
Center: J. L. P. Thompson, B. Levin, R. Buchsbaum, M. Del Valle, A. Sanford, G. Levy, K. Tea, 
J. Grier, L. Swydan, B. O’Hare, R. Prodhan, R. Arbing, E. Flanagan, E. Duverger, A. Peljto, W. 
Lo, A. Tierney, A. Henriquez, and J. Keen; Data and Safety Monitoring Board: G.J. del Zoppo, 
G.W. Albers, M. Eliasziw, J.A. Hinchey, K.C. Johnston, A.M. Lowe, I.L. Piña and J.A. Swain;  
 
Endpoint Adjudication Committee 
J.R. Teerlink, S. Ammon, S. Slomiak, and L. Cape; Neurology Adjudicators: H.J.M. Barnett, A. 
Bruno, J.D. Easton, S. Levine, and D. Sahlas; Cardiology Adjudicators: F. Bleyer, P. Carson, A. 
Ellis, A. Miller, and S.T. Palmeri;  
 
Core Echo Lab 
A.Labovitz, M. Di Tullio, M.Bierig, R. Liu, and C. Donato; Hemorrhage adjudicator: R. Hart.  
 
Clinical Research Organizations 
Clinsys (United States and Canada): C. McKay, L. Wilson, E. Frey, K. Hayward, P. Stein-Beal 
and L. Konczarek; Charite (Germany, Poland and etherlands): M. Diek, M. Rohwedder, M. 
Bohdanowicz-Zazula, C.F. Peerenboom-Fey and M. Vissiennon; Verum (Hungary and Ukraine): 
G. Rex, M. Varga, O. Kovtun and V. Orlyk; FGK (Czech Republic and Slovakia): P. Arenberger 
and J. Jaros. STAT Research (Argentina): A. Ruiz, M. Zimmermann and A. Ellenberg.  
 
Complete list of WARCEF Sites 
The following institutions, investigators, and coordinators enrolled patients in the trial (shown in 
parenthesis is the number of patients randomized at the site): United States, LSU Health 
Sciences Center (66): A. Minagar, R. Kelley, J. McGee, P. Jinkins, and S. Bezucha; Buffalo 
General Hospital (53): S. Graham, V. Hart, M. Bonora, R. Sawyer, and K. Ammerman; Detroit 
VA Medical Center (50): P. Ramappa, V. Berchou, E. Jones, and E. Olgren; Denver VA Medical 
Center (38): B. Hattler, C. Anderson, B. Watson, and D. Wolf; UMDNJ - New Brunswick (29): J. 
Kosits, S. Palmeri, and L. Casazza; Mayo Clinic – Transplant Center (28): D. Yip, J. Meschia, A. 
McPhail, and K. Greenan; LeBauer Cardiovascular Research (28): R. Rothbart, J. Love, T. 
Schrader, and V. Garman; Louisville VA Medical Center (27): M. Stoddard, K. Remmel, and R. 
Longaker; UMDNJ - Newark (26): C. Gerula, M. Klapholz, J. Kirmani, and R. Mattessich; 
Columbia University Medical Center (24): M. Di Tullio, C. Rodriguez, and A. Gabriel; Reno VA 
Medical Center (22): W. Graettinger, A. Baker, and A. Valencia; Madison VA Medical Center 
(22): P. Kosolcharoen, and L. Williams; University of Arizona Health Sciences Center (21): V. 
Sorrell, B. Coull, and D. Bruck; Morehouse School of Medicine (20): E. Ofili, M. Frankel, and P. 
Jackson; Cardiac Care and Vascular Medicine, PLLC (20): M. Nanna, J. Yasen, S. Sparr, and 
W. Almeida; Long Island Jewish Medical Center (20): R. Libman, B. Stephens, and C. DeMers; 
Gulf Regional Research, LLC (20): T. Giles, L. Roffidal, and D. Barratt; Veterans Affairs Medical 
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Center (19): M. Liston, C. Lindsey, and L. Giron; Virginia Commonwealth University (18): W. 
Felton III, L. Joseph, and M. Lee; University of Rochester Medical Center (16): J. Bisognano, C. 
Benesch, and L. Caufield; Santa Clara Medical Center (16): E. Nishime, M. Moussavian, and E. 
Polland; Black Hills Health Care System (16): L. Fischer, K. Peterson, and B. McGinnis; Lahey 
Clinic (15): M. Tilem, G. Allam, and J. Beebe; University of North Carolina at Chapel Hill (14): P. 
Chang, S. Sen, and C. Schuler; L.J. Chabert Medical Center (14): L. Arcement, M. Charlet, and 
E. Falgout; Sewickley Valley Medical Group, Cardiology (14): M. Malkowski, T. Dugan, and J. 
Hobbs-Williams; West Los Angeles VA Medical Center (14): A. Warner, K. Panizzon, and J. 
Johnson; Albert Einstein Medical Center (13): J. Dissin, D. Karia, and N. Molakala; Melbourne 
Internal Medicine Associates (11): B. Dandapani, R. Vicari, and E. Anthony; The Cleveland 
Clinic Foundation (11): I. Katzan, R. Hobbs, and A. Richmond; Denver Health Medical Center 
(11): R. Hughes, W. Baker, and M Applegate; Penn Presbyterian Medical Center (11): B. 
Drachman, S. Khella, and S. Donovan; Brooke Army Medical Center MCHE - MDC Cardiology 
Service (10): A. Slim, and D. Pearce Moore; Mount Sinai Medical Center (10): B. Darrow, and A. 
Travis; The Westchester Medical Group (10): A. Mercando, and R. Pellegrino; Salem VA 
Medical Center (10): N. Jarmukli, and T. Ochalek; St. Louis University Hospital (9): D. Janosik, 
and J. Dizes; University of Kentucky (9): L.C. Pettigrew, and D. Taylor; MetroHealth Medical 
Center (7): J. Hanna, and S. Bailey; Hackensack University Medical Center (7): R. Berkowitz, 
and S. Mathus; Huntington VA Medical Center (6) V. Virkud, and S. Shaw; Lehigh Valley 
Hospital (6): R. Freudenberger, and S. Nabhan; Winthrop University Hospital (5): E. Wirkowski, 
and B. George; Central Arkansas VA Medical Center (5):E. Smith, and S. Locke; Connecticut 
Heart and Vascular Center, PC (5): C. Landau, and D.Ferguson; University of Texas Medical 
School - Houston (5): H.V. Anderson, and L. Westbrook; Cincinnati VA Medical Center (5): M. 
Apelian, and S. Khoury; Berkshire Medical Center (5): J. Leppo, and T. Bator; Richmond VA 
Medical Center (4): W. Felton III, and M. Lee; University of Louisville (4): M. Stoddard, and R. 
Longaker; Oklahoma City VA Medical Center (4): U. Thadani, and J. Turner; Southern Arizona 
VA Health Care System (4): S. Goldman, and S. Daugherty; Methodist Heart, Lung and 
Vascular Institute (4): A. Adler, and T. Rennie; Tri-State Medical Group Cardiology (4): M. 
Malkowski, and D. Chupka; George Washington University (4): R. Katz, and L. Witkin; 
Rochester General Hospital (3): W. S. Burgin, and C. Weber; Penn State Milton S. Hershey 
Medical Center (3): J. Boehmer, and P. Frey; Kaleida Health Millard Fillmore Hospital (3): M. 
Wilson, and H. Tworek; Northport VA Medical Center (3): G. Mallis, and D. Mauceri; Holy Cross 
Medical Group (3): R. Schneider, and W. Schneider; Jackson Memorial Hospital (3): G. Ortiz, 
and M. Lichtenberger; Northeast Georgia Heart Center (3): B. Hott, and D. Patrick; Rush 
University Medical Center (2): S. Dunlap, and S.J. Kim; Fallon Clinic, Inc. (2): S. Pezzella, and 
D. Aubin; Temple University Hospital (2): L. Nikolaidis, and J. Wong; North Shore University 
Hospital (1): D. Leifer, and M. Rossi; Methodist Hospital - Physician Association (1): G. Torre, 
and J. Arredondo; Mayo Clinic Scottsdale (1): J. Lynch, and A. Metcalf; Watson Clinic Center for 
Research, Inc. (1): J. Gonzalez, and B. Donley; Hospital of the University of Pennsylvania (1): T. 
Cappola, and K. Craig; Houston VA Medical Center (1): B. Bozkurt, and M. Bolos; Blackstone 
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